This Day On The Street
Continue to site right-arrow
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
Stocks Under $10 with 50-100% upside potential - 14 days FREE!

The Institute For Systems Biology Places A Third Order For Sequencing Services With Complete Genomics, Includes 615 Genomes

MOUNTAIN VIEW, Calif., Jan. 11, 2011 (GLOBE NEWSWIRE) -- The Institute for Systems Biology (ISB) and Complete Genomics Inc. (Nasdaq:GNOM) announced today the signing of an agreement that calls for Complete Genomics to sequence 615 complete human genome samples as part of an ISB study on neurodegenerative diseases.

In 2009, ISB engaged Complete Genomics to sequence four genomes as part of a small family study to verify the causal gene in Miller syndrome. This initial project resulted in a publication in Science 1 that also documented the low error rates in the data generated by Complete Genomics.

More recently, in early 2010, ISB engaged Complete Genomics to sequence 100 genomes for multiple family studies of Huntington's and other diseases in collaboration with several academic institutions. These studies have demonstrated even lower error rates than the data generated in 2009.

"Over the past two years, Complete Genomics has played a critical role in our investigation of several diseases in multigenerational families. Its proven complete human genome sequencing service has helped our scientists in these detailed genetic analyses. The Miller syndrome study by ISB, the University of Utah and the University of Washington, was groundbreaking," said ISB Senior Vice President for Strategic Partnerships David Galas.

"Partnering with Complete Genomics for our human sequencing needs has allowed us to focus on data analysis and interpretation while avoiding major capital expense, pipeline building and technology development. Their continuous increase in sequencing accuracy and coverage has allowed us to generate highly accurate results," said ISB President Dr. Leroy Hood. All of the work at ISB on these projects has been supported by the partnership between ISB and the University of Luxembourg, in particular with the Luxembourg Centre for Systems Biomedicine.

Neurodegenerative diseases cover a broad range of disorders that affect neurons, or neuromuscular control, many of which are genetic or hereditary in nature, such as Huntington's disease. For this study, ISB will, in coordination with its academic partners, supply the purified DNA samples from families with multiple affected individuals. Complete Genomics will perform the sequencing, assembly and annotation and deliver to ISB a listing of variations found in each genome. ISB will then do its own further analysis, utilizing the power of family genetics and network analysis with the data sets to identify causal and modifying genes.

1 of 3

Select the service that is right for you!

Action Alerts PLUS
Try it NOW

Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
  • Weekly roundups
TheStreet Quant Ratings
Try it NOW
Only $49.95/yr

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
  • Upgrade/downgrade alerts
Stocks Under $10
Try it NOW

David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
  • Weekly roundups
Dividend Stock Advisor
Try it NOW

Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Alerts when market news affect the portfolio
  • Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
Real Money Pro
Try it NOW

All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.

Product Features:
  • Real Money + Doug Kass Plus 15 more Wall Street Pros
  • Intraday commentary & news
  • Ultra-actionable trading ideas
Options Profits
Try it NOW

Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • 100+ monthly options trading ideas
  • Actionable options commentary & news
  • Real-time trading community
  • Options TV
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!


DOW 17,804.80 +26.65 0.15%
S&P 500 2,070.65 +9.42 0.46%
NASDAQ 4,765.38 +16.9840 0.36%

Brokerage Partners

Rates from

  • Mortgage
  • Credit Cards
  • Auto

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs